Is silencing of HEPN1 responsible for the aggressive biological behavior of pituitary somatotroph adenomas?
Taken together, our results suggest that reduction of HEPN1 may play an important role in the progression of pituitary somatotroph adenomas. HEPN1 may thus be a candidate as a prognostic predictor or an anticancer therapeutic target for patients with somatotroph adenoma.
Oral administration of compound 10b effectively attenuates rat cerebral ischemia injury.